You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Commercializing the Effective K-3 Assessment to Instruction (A2i) Intervention to Reduce Cost and to Scale Access to the Benefit of More Students
SBC: Learning Ovations, Inc. Topic: N/APurpose: Students who fail to achieve proficient levels of literacy are at increased risk for grade retention, referral to special education, and dropping out of high school. The kindergarten through 3rd grade years are particularly important for students to gain a strong foundation in reading as those who continue to struggle with reading are significantly less likely to achieve reading proficien ...
SBIR Phase I 2014 Department of Education -
Commercializing the Effective K-3 Assessment to Instruction (A2i) Intervention to Reduce Cost and to Scale Access to the Benefit of More Students
SBC: Learning Ovations, Inc. Topic: N/APurpose: Students who fail to achieve proficient levels of literacy are at increased risk for grade retention, referral to special education, and dropping out of high school. The kindergarten through 3rd grade years are particularly important for students to gain a strong foundation in reading as those who continue to struggle with reading are significantly less likely to achieve reading proficien ...
SBIR Phase II 2014 Department of Education -
Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids
SBC: L2 DIAGNOSTICS LLC Topic: NIAIDDESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; however, there is currently no cure for the disease. Discovery that a naturally occurring variant of CCR5, the delta32 mutation, renders cells resistant to HIV infection has led to efforts by several a ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Formulation of LbL microparticle vaccine in microneedle array for intradermal del
SBC: ARTIFICIAL CELL TECHNOLOGIES INC Topic: NIAIDAbstract The ability of the immune system to recognize and initiate an immune response to foreign particles such as bacteria and viruses has generated interest in development of particulate vaccine technologies. We are developing an innovative approach toproduce particulate vaccines via layer-by-layer (LbL) fabrication of synthetic microparticles (MP). We have shown that LbL-MP loaded with epitope ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Immune-based brain cancer diagnostic for rapid, accurate disease classification
SBC: HealthTell Inc. Topic: NCIDESCRIPTION (provided by applicant): Accurate, early disease diagnosis and monitoring are critical aspects to effective prevention, treatment, and remission of disease. Most diagnostic methods available today are not simple or sensitive enough to significantly impact patients' response to treatment or survival outcome. This unmet need is highlighted by diseases, such as brain cancers, that o ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain
SBC: HALIMED PHARMACEUTICALS, INC. Topic: NIDADESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Engineered Neurotensin Fragments Targeting Neuropathic Pain
SBC: JT Pharmaceuticals, Inc. Topic: NIDCRDESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals donot respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as an alternative; however, the only succ ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a lasmiditan analogue for treatment of acute kidney injury
SBC: Mitohealth, Inc Topic: NIDDKDESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R)or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Enhancing longevity of implanted medical devices
SBC: PIEZO ENERGY TECHNOLOGIES LLC Topic: NIBIBDESCRIPTION provided by applicant Advanced methods for wirelessly recharging batteries for implanted medical devices are needed The useful lifetime of most implants is constrained by the longevity of the power source The goal of this program is to implement the development of an UltraSound Electrical Recharging system USerTM within a clinically deployed gastric sphincter stimulation system ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Sterculic Acid Analogs to Inhibit Macular Degeneration
SBC: L2 DIAGNOSTICS LLC Topic: NEIABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health